Does the media favor CV or MBOT?

In the previous week, Microbot Medical had 1 more articles in the media than CapsoVision. MarketBeat recorded 4 mentions for Microbot Medical and 3 mentions for CapsoVision. Microbot Medical's average media sentiment score of 0.70 beat CapsoVision's score of -0.36 indicating that Microbot Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CapsoVision 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Microbot Medical 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MBOT or MOBI more profitable?

Mobia Medical's return on equity of 0.00% beat Microbot Medical's return on equity. Company Net Margins Return on Equity Return on Assets Microbot Medical N/A -21.87% -20.76% Mobia Medical N/A N/A N/A

Does the media refer more to MBOT or MOBI?

In the previous week, Mobia Medical had 1 more articles in the media than Microbot Medical. MarketBeat recorded 5 mentions for Mobia Medical and 4 mentions for Microbot Medical. Microbot Medical's average media sentiment score of 0.70 beat Mobia Medical's score of 0.34 indicating that Microbot Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Microbot Medical 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mobia Medical 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TLSI or MBOT?

In the previous week, TriSalus Life Sciences had 2 more articles in the media than Microbot Medical. MarketBeat recorded 6 mentions for TriSalus Life Sciences and 4 mentions for Microbot Medical. Microbot Medical's average media sentiment score of 0.70 beat TriSalus Life Sciences' score of -0.13 indicating that Microbot Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Microbot Medical 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Microbot Medical (MBOT) Competitors

$1.07 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.09 +0.02 (+1.87%)

As of 10/9/2026 07:47 PM Eastern

Compare

MBOT vs. CV, MOBI, TMCI, TLSI, and ELMD

Should you buy Microbot Medical stock or one of its competitors? Microbot Medical's main competitors and comparable companies include CapsoVision (CV), Mobia Medical (MOBI), Treace Medical Concepts (TMCI), TriSalus Life Sciences (TLSI), and Electromed (ELMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Microbot Medical compare to CapsoVision?

CapsoVision (NASDAQ:CV) and Microbot Medical (NASDAQ:MBOT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

16.3% of Microbot Medical shares are owned by institutional investors. 2.3% of CapsoVision shares are owned by insiders. Comparatively, 4.7% of Microbot Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CapsoVision presently has a consensus price target of $9.50, indicating a potential upside of 44.16%. Microbot Medical has a consensus price target of $6.38, indicating a potential upside of 495.79%. Given Microbot Medical's stronger consensus rating and higher probable upside, analysts plainly believe Microbot Medical is more favorable than CapsoVision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Microbot Medical has a net margin of 0.00% compared to CapsoVision's net margin of -214.74%. Microbot Medical's return on equity of -21.87% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CapsoVision	-214.74%	-177.85%	-135.07%
Microbot Medical	N/A	-21.87%	-20.76%

In the previous week, Microbot Medical had 1 more articles in the media than CapsoVision. MarketBeat recorded 4 mentions for Microbot Medical and 3 mentions for CapsoVision. Microbot Medical's average media sentiment score of 0.70 beat CapsoVision's score of -0.36 indicating that Microbot Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CapsoVision	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Microbot Medical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Microbot Medical has lower revenue, but higher earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CapsoVision	$13.55M	24.34	-$25.32M	-$0.47	N/A
Microbot Medical	$346K	207.71	-$13.14M	-$0.24	N/A

CapsoVision has a beta of -2.45, meaning that its share price is 345% less volatile than the broader market. Comparatively, Microbot Medical has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Summary

Microbot Medical beats CapsoVision on 15 of the 16 factors compared between the two stocks.

How does Microbot Medical compare to Mobia Medical?

Microbot Medical (NASDAQ:MBOT) and Mobia Medical (NASDAQ:MOBI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations and media sentiment.

Microbot Medical has higher earnings, but lower revenue than Mobia Medical. Microbot Medical is trading at a lower price-to-earnings ratio than Mobia Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	$346K	207.71	-$13.14M	-$0.24	N/A
Mobia Medical	$32.04M	8.97	-$46.50M	-$20.18	N/A

Microbot Medical currently has a consensus target price of $6.38, indicating a potential upside of 495.79%. Mobia Medical has a consensus target price of $20.75, indicating a potential upside of 140.44%. Given Microbot Medical's higher probable upside, research analysts clearly believe Microbot Medical is more favorable than Mobia Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Mobia Medical	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Mobia Medical had 1 more articles in the media than Microbot Medical. MarketBeat recorded 5 mentions for Mobia Medical and 4 mentions for Microbot Medical. Microbot Medical's average media sentiment score of 0.70 beat Mobia Medical's score of 0.34 indicating that Microbot Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Microbot Medical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mobia Medical	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mobia Medical's return on equity of 0.00% beat Microbot Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-21.87%	-20.76%
Mobia Medical	N/A	N/A	N/A

16.3% of Microbot Medical shares are owned by institutional investors. 4.7% of Microbot Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Microbot Medical and Mobia Medical tied by winning 7 of the 14 factors compared between the two stocks.

How does Microbot Medical compare to Treace Medical Concepts?

Treace Medical Concepts (NASDAQ:TMCI) and Microbot Medical (NASDAQ:MBOT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

In the previous week, Microbot Medical had 3 more articles in the media than Treace Medical Concepts. MarketBeat recorded 4 mentions for Microbot Medical and 1 mentions for Treace Medical Concepts. Microbot Medical's average media sentiment score of 0.70 beat Treace Medical Concepts' score of 0.00 indicating that Microbot Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Treace Medical Concepts	Neutral
Microbot Medical	Positive

Microbot Medical has a net margin of 0.00% compared to Treace Medical Concepts' net margin of -28.99%. Microbot Medical's return on equity of -21.87% beat Treace Medical Concepts' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Treace Medical Concepts	-28.99%	-71.37%	-30.49%
Microbot Medical	N/A	-21.87%	-20.76%

Microbot Medical has lower revenue, but higher earnings than Treace Medical Concepts. Microbot Medical is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Treace Medical Concepts	$212.69M	1.21	-$59M	-$0.93	N/A
Microbot Medical	$346K	207.71	-$13.14M	-$0.24	N/A

Treace Medical Concepts presently has a consensus target price of $5.17, indicating a potential upside of 30.89%. Microbot Medical has a consensus target price of $6.38, indicating a potential upside of 495.79%. Given Microbot Medical's stronger consensus rating and higher possible upside, analysts clearly believe Microbot Medical is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Treace Medical Concepts has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market. Comparatively, Microbot Medical has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

84.1% of Treace Medical Concepts shares are held by institutional investors. Comparatively, 16.3% of Microbot Medical shares are held by institutional investors. 23.4% of Treace Medical Concepts shares are held by company insiders. Comparatively, 4.7% of Microbot Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Microbot Medical beats Treace Medical Concepts on 11 of the 16 factors compared between the two stocks.

How does Microbot Medical compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and Microbot Medical (NASDAQ:MBOT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

TriSalus Life Sciences has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Microbot Medical has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 16.3% of Microbot Medical shares are owned by institutional investors. 16.3% of TriSalus Life Sciences shares are owned by insiders. Comparatively, 4.7% of Microbot Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, TriSalus Life Sciences had 2 more articles in the media than Microbot Medical. MarketBeat recorded 6 mentions for TriSalus Life Sciences and 4 mentions for Microbot Medical. Microbot Medical's average media sentiment score of 0.70 beat TriSalus Life Sciences' score of -0.13 indicating that Microbot Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Microbot Medical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Microbot Medical has lower revenue, but higher earnings than TriSalus Life Sciences. Microbot Medical is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.08M	5.55	-$39.23M	-$1.30	N/A
Microbot Medical	$346K	207.71	-$13.14M	-$0.24	N/A

TriSalus Life Sciences currently has a consensus target price of $10.20, indicating a potential upside of 151.23%. Microbot Medical has a consensus target price of $6.38, indicating a potential upside of 495.79%. Given Microbot Medical's higher possible upside, analysts clearly believe Microbot Medical is more favorable than TriSalus Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Microbot Medical has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -62.59%. TriSalus Life Sciences' return on equity of 0.00% beat Microbot Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-62.59%	N/A	-64.47%
Microbot Medical	N/A	-21.87%	-20.76%

Summary

Microbot Medical beats TriSalus Life Sciences on 9 of the 14 factors compared between the two stocks.

How does Microbot Medical compare to Electromed?

Electromed (NYSE:ELMD) and Microbot Medical (NASDAQ:MBOT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Electromed has a net margin of 11.34% compared to Microbot Medical's net margin of 0.00%. Electromed's return on equity of 15.71% beat Microbot Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Microbot Medical	N/A	-21.87%	-20.76%

Electromed has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$73.78M	3.11	$5.15M	$1.31	21.14
Microbot Medical	$346K	207.71	-$13.14M	-$0.24	N/A

Electromed has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, Microbot Medical has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

Electromed currently has a consensus target price of $43.75, indicating a potential upside of 58.00%. Microbot Medical has a consensus target price of $6.38, indicating a potential upside of 495.79%. Given Microbot Medical's higher probable upside, analysts plainly believe Microbot Medical is more favorable than Electromed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Microbot Medical had 4 more articles in the media than Electromed. MarketBeat recorded 4 mentions for Microbot Medical and 0 mentions for Electromed. Electromed's average media sentiment score of 1.84 beat Microbot Medical's score of 0.70 indicating that Electromed is being referred to more favorably in the media.

Company	Overall Sentiment
Electromed	Very Positive
Microbot Medical	Positive

40.8% of Electromed shares are held by institutional investors. Comparatively, 16.3% of Microbot Medical shares are held by institutional investors. 11.0% of Electromed shares are held by company insiders. Comparatively, 4.7% of Microbot Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Electromed beats Microbot Medical on 11 of the 15 factors compared between the two stocks.

Get Microbot Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBOT vs. The Competition

Export

Metric	Microbot Medical	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$71.87M	$5.44B	$7.17B	$13.21B
Dividend Yield	N/A	1.78%	2.53%	16.37%
P/E Ratio	-4.46	25.57	274.15	26.16
Price / Sales	207.71	83.34	635.99	107.44
Price / Cash	N/A	31.87	76.38	53.09
Price / Book	0.93	5.95	11.22	6.33
Net Income	-$13.14M	$146.18M	$3.50B	$382.15M
7 Day Performance	-7.76%	-0.28%	-0.90%	-1.40%
1 Month Performance	-26.71%	-1.88%	-4.44%	-3.47%
1 Year Performance	-63.36%	5.45%	7.02%	1.19%

Microbot Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBOT Microbot Medical	3.5014 of 5 stars	$1.07 flat	$6.38 +495.8%	-66.2%	$71.87M	$346K	N/A	22
CV CapsoVision	3.2776 of 5 stars	$6.59 +6.8%	$9.50 +44.2%	+42.0%	$308.79M	$13.89M	N/A	99
MOBI Mobia Medical	3.7864 of 5 stars	$9.59 +4.5%	$20.75 +116.4%	N/A	$305.61M	$45.28M	N/A	167	Short Interest Increase
TMCI Treace Medical Concepts	2.4445 of 5 stars	$4.48 +2.1%	$5.17 +15.4%	-34.5%	$285.50M	$212.69M	N/A	450
TLSI TriSalus Life Sciences	2.2525 of 5 stars	$4.38 +1.4%	$10.20 +132.9%	-8.1%	$266M	$45.15M	N/A	102

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBOT) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Microbot Medical (MBOT) Competitors

MBOT vs. CV, MOBI, TMCI, TLSI, and ELMD

How does Microbot Medical compare to CapsoVision?

Summary

How does Microbot Medical compare to Mobia Medical?

Summary

How does Microbot Medical compare to Treace Medical Concepts?

Summary

How does Microbot Medical compare to TriSalus Life Sciences?

Summary

How does Microbot Medical compare to Electromed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBOT vs. The Competition

Microbot Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Microbot Medical (MBOT) Competitors

MBOT vs. CV, MOBI, TMCI, TLSI, and ELMD

How does Microbot Medical compare to CapsoVision?

Do institutionals & insiders have more ownership in CV or MBOT?

Do analysts prefer CV or MBOT?

Is CV or MBOT more profitable?

Does the media favor CV or MBOT?

Which has preferable earnings & valuation, CV or MBOT?

Which has more risk & volatility, CV or MBOT?

Summary

How does Microbot Medical compare to Mobia Medical?

Which has stronger earnings and valuation, MBOT or MOBI?

Do analysts recommend MBOT or MOBI?

Does the media refer more to MBOT or MOBI?

Is MBOT or MOBI more profitable?

Do insiders and institutionals believe in MBOT or MOBI?

Summary

How does Microbot Medical compare to Treace Medical Concepts?

Does the media favor TMCI or MBOT?

Is TMCI or MBOT more profitable?

Which has higher earnings & valuation, TMCI or MBOT?

Do analysts recommend TMCI or MBOT?

Which has more volatility and risk, TMCI or MBOT?

Do insiders & institutionals have more ownership in TMCI or MBOT?

Summary

How does Microbot Medical compare to TriSalus Life Sciences?

Which has more volatility and risk, TLSI or MBOT?

Do insiders and institutionals believe in TLSI or MBOT?

Does the media favor TLSI or MBOT?

Which has preferable valuation and earnings, TLSI or MBOT?

Do analysts prefer TLSI or MBOT?

Is TLSI or MBOT more profitable?

Summary

How does Microbot Medical compare to Electromed?

Is ELMD or MBOT more profitable?

Which has better valuation & earnings, ELMD or MBOT?

Which has more risk & volatility, ELMD or MBOT?

Do analysts rate ELMD or MBOT?

Does the media prefer ELMD or MBOT?

Do insiders & institutionals have more ownership in ELMD or MBOT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBOT vs. The Competition

Microbot Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools